Evidence map›Paper›PMID 35155485›Full record

ArticleFrontiers in medicine2021

COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases.

Borja Del Carmelo Gracia, Luis Sáez, Lucio Pallarés, Jose Velilla, Adela Marín, Luis Martinez-Lostao, Carmen Pilar Simeón, Patricia Fanlo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Borja Del Carmelo GraciaSytemic Autoimmune Diseases Unit, Internal Medicine Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain.
Luis SáezSytemic Autoimmune Diseases Unit, Internal Medicine Department, Miguel Servet University Clinical Hospital, Zaragoza, Spain.
Lucio PallarésSytemic Autoimmune Diseases Unit, Internal Medicine Department, Son Espases University Clinical Hospital, Palma de Mallorca, Spain.
Jose VelillaSytemic Autoimmune Diseases Unit, Internal Medicine Department, Miguel Servet University Clinical Hospital, Zaragoza, Spain.
Adela MarínSytemic Autoimmune Diseases Unit, Internal Medicine Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain.
Luis Martinez-LostaoImmunology Department, Lozano Blesa University Hospital, Zaragoza, Spain.
Carmen Pilar SimeónSystemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Patricia FanloSystemic Autoimmune Diseases Unit, Internal Medicine Department, Universitary Complex of Navarra, Pamplona, Spain.
Hospital Clínico Universitario Lozano Blesa · ESHospital Universitario Miguel Servet · ESHospital Universitario Son Espases · ESUniversidad de Navarra · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCOVID-19 outcomes in population with systemic autoimmune diseases (SAD) remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 infection in people with rheumatic disease.

methodsTwo phases cross-sectional survey of individuals with rheumatic disease in April 2020 and October 2020. COVID infection, severity of disease, age, sex, smoking status, underlying rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analyzed.

resultsA total of 1,529 individuals with autoimmunity disease diagnosis were included. Out of 50 positive patients, 21 required telephone medical assistance, 16 received assessment by primary care physician, 9 were evaluated in Emergency Department and 4 patient required hospitalization. Multivariate analysis was performed without obtaining differences in any of the systemic autoimmune diseases. Regarding the treatments, significant differences were found (

conclusionsAnti-TNF-alpha treatment was associated with more than 3-fold risk of suffering from SARS-CoV-2 infection, although in all cases infection was mild. Cumulative incidence in patients with SAD was up to 5 times higher than general population but with great differences between autoimmune diseases.

Indexed as

anti-TNFcorticosteroidsCOVID-19 infectionSARS-CoV-2surveysystemic autoimmune diseasesystemic erythematosus lupus

Identifiers

PMID35155485
PMCPMC8828974
OpenAlexW4210739436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.